DarioHealth (NASDAQ:DRIO) vs. Echo Therapeutics (OTCMKTS:ECTE) Financial Review

DarioHealth (NASDAQ:DRIO) and Echo Therapeutics (OTCMKTS:ECTE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares DarioHealth and Echo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	-192.23%	-60.52%	-37.08%
Echo Therapeutics	N/A	N/A	N/A

Earnings and Valuation

This table compares DarioHealth and Echo Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36 million	2.23	-$41.71 million	($8.88)	-0.77
Echo Therapeutics	N/A	N/A	N/A	N/A	N/A

Echo Therapeutics has lower revenue, but higher earnings than DarioHealth.

Analyst Recommendations

This is a summary of current recommendations and price targets for DarioHealth and Echo Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1	1	1	0	2.00
Echo Therapeutics	0	0	0	0	0.00

DarioHealth currently has a consensus price target of $10.50, indicating a potential upside of 54.19%. Given DarioHealth’s stronger consensus rating and higher probable upside, research analysts clearly believe DarioHealth is more favorable than Echo Therapeutics.

Insider and Institutional Ownership

33.4% of DarioHealth shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by company insiders. Comparatively, 7.0% of Echo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

DarioHealth beats Echo Therapeutics on 5 of the 9 factors compared between the two stocks.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

About Echo Therapeutics

Echo Therapeutics, Inc. is a medical device company, which engages in the development of non-invasive, and wireless continuous glucose monitoring system for use in the diabetes outpatient market. It offers needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose and delivery of topical pharmaceuticals. The company was founded in 1989 and is headquartered in Iselin, NJ.